Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Dec 4;20(12):21658-71.
doi: 10.3390/molecules201219797.

Pharmaceutical Potential of Synthetic and Natural Pyrrolomycins

Stella Cascioferro  1   2 , Maria Valeria Raimondi  3 , Maria Grazia Cusimano  4 , Demetrio Raffa  5 , Benedetta Maggio  6 , Giuseppe Daidone  7 , Domenico Schillaci  8
Affiliations
Review

Pharmaceutical Potential of Synthetic and Natural Pyrrolomycins

Stella Cascioferro et al. Molecules. .

Abstract

The emergence of antibiotic resistance is currently considered one of the most important global health problem. The continuous onset of multidrug-resistant Gram-positive and Gram-negative bacterial strains limits the clinical efficacy of most of the marketed antibiotics. Therefore, there is an urgent need for new antibiotics. Pyrrolomycins are a class of biologically active compounds that exhibit a broad spectrum of biological activities, including antibacterial, antifungal, anthelmintic, antiproliferative, insecticidal, and acaricidal activities. In this review we focus on the antibacterial activity and antibiofilm activity of pyrrolomycins against Gram-positive and Gram-negative pathogens. Their efficacy, combined in some cases with a low toxicity, confers to these molecules a great potential for the development of new antimicrobial agents to face the antibiotic crisis.

Keywords: antibiofilm agents; antibiotic resistance; pentabromopseudilin; pyoluteorin; pyrrolomycins.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structures of compounds 1–4.
Figure 2
Figure 2
Structure of pyrrolnitrin 5.
Figure 3
Figure 3
Structures of pyrrolomycins A, B, C, D, E, G, H, I, J and dioxapyrrolomycin.
Figure 4
Figure 4
Chemical structures of pyrrolomycins F.
Figure 5
Figure 5
Structures of compounds 7–16.
Figure 6
Figure 6
Structures of derivatives 17a–c and 4.
Figure 7
Figure 7
Structures of compounds 20a–e.
See this image and copyright information in PMC

References

    1. Centers of Diseases Control and Prevention. [(accessed on 2 December 2015)]; Available online: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
    1. Cascioferro S., Cusimano M.G., Schillaci D. Antiadhesion agents against Gram-positive pathogens. Future Microbiol. 2014;9:1209–1220. doi: 10.2217/fmb.14.56. - DOI - PubMed
    1. Cascioferro S., Totsika M., Schillaci D. Sortase A: An ideal target for anti-virulence drug development. Microb. Pathog. 2014;77C:105–112. doi: 10.1016/j.micpath.2014.10.007. - DOI - PubMed
    1. Penesyan A., Gillings M., Paulsen I.T. Antibiotic discovery: Combatting bacterial resistance in cells and in biofilm communities. Mol. Basel Switz. 2015;20:5286–5298. doi: 10.3390/molecules20045286. - DOI - PMC - PubMed
    1. Cascioferro S., Schillaci D. The Future of Antibiotic: From the Magic Bullet to the Smart Bullet. J. Microb. Biochem. Technol. 2014;6:e118. doi: 10.4172/1948-5948.1000e118. - DOI

LinkOut - more resources